Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25Deepening responses observed over time in ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its ...

Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2025 strategic priorities across its pipeline of mRNA cell ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...

(ARGX0 stock was downgraded to Sell by Deutsche Bank on valuation concerns and potential competition on Friday. Read more here.

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years.

There's a lot of brain power that goes into speech. First, there's a thought or idea, which the brain must translate into ...